The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation
AI-extracted · unverified · confirm at source
Comprehensive cardiac review: hERG IC₅₀ ~4 μM overlaps therapeutic range; 22 fatalities tabulated with 100% hypokalemia when tested; noribogaine half-life (28–49 h) extends cardiac risk beyond acute phase.
Dosing: 4.5–29 mg/kg (fatality cases); therapeutic 10–25 mg/kg (oral)
Safety data present: QTC, HERG, ELECTROLYTE
Contraindications: hypokalaemia, hypomagnesaemia, cardiovascular disease, prolonged baseline QT interval, bradycardia, female gender, hERG channel mutations, CYP2D6 inhibitors, CYP2D6 poor metaboliser genetic status (altered PK; potential weeks-long cardiotoxicity from single dose), methadone co-use, cocaine co-use, alcohol co-use, diazepam co-use, hepatic impairment (hepatitis, liver cirrhosis), concurrent QT-prolonging medications, unsupervised or unmonitored administration